keyword
MENU ▼
Read by QxMD icon Read
search

Ustekinumab pharmacokinetics

keyword
https://www.readbyqxmd.com/read/27610650/target-independent-variable-region-mediated-effects-on-antibody-clearance-can-be-fcrn-independent
#1
Ryan L Kelly, Yao Yu, Tingwan Sun, Isabelle Caffry, Heather Lynaugh, Michael Brown, Tushar Jain, Yingda Xu, K Dane Wittrup
The importance of the neonatal Fc receptor (FcRn) in extending the serum half-life of monoclonal antibodies (mAbs) is well demonstrated, and has led to the development of multiple engineering approaches designed to alter Fc interactions with FcRn. Recent reports have additionally highlighted the effect of nonspecific interactions on antibody pharmacokinetics (PK), suggesting an FcRn-independent mechanism for mAb clearance. In this report we examine a case study of 2 anti-interleukin-12/23 antibodies, ustekinumab and briakinumab, which share the same target and Fc, but differ in variable region sequences...
October 2016: MAbs
https://www.readbyqxmd.com/read/26488186/the-cost-effectiveness-of-ustekinumab-for-moderate-to-severe-psoriasis
#2
REVIEW
Nicole C Rouse, Michael E Farhangian, Brooke Wehausen, Steven R Feldman
Given its chronicity and impact on quality of life, psoriasis is a costly disease. As new and better treatments are developed, the cost of treating psoriasis has risen. In this drug profile, the authors discuss ustekinumab, its pharmacokinetics, safety profile, and direct and indirect costs to determine its cost-efficacy. The authors searched PubMed with specific search phrases for clinical trials investigating this issue over 5 years. Eleven articles analyzed cost-effectiveness of ustekinumab, and the references of these articles were included...
2015: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/25918417/charge-mediated-influence-of-the-antibody-variable-domain-on-fcrn-dependent-pharmacokinetics
#3
Angela Schoch, Hubert Kettenberger, Olaf Mundigl, Gerhard Winter, Julia Engert, Julia Heinrich, Thomas Emrich
Here, we investigated the influence of the variable fragment (Fv) of IgG antibodies on the binding to the neonatal Fc receptor (FcRn) as well as on FcRn-dependent pharmacokinetics (PK). FcRn plays a key role in IgG homeostasis, and specific manipulation in the crystallizable fragment (Fc) is known to affect FcRn-dependent PK. Although the influence of the antigen-binding fragment (Fab) on FcRn interactions has been reported, the underlying mechanism is hitherto only poorly understood. Therefore, we analyzed the two IgG1 antibodies, briakinumab and ustekinumab, that have similar Fc parts but different terminal half-lives in human and systematically engineered variants of them with cross-over exchanges and varied charge distribution...
May 12, 2015: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/25284845/biologics-in-dermatology-an-integrated-review
#4
REVIEW
Virendra N Sehgal, Deepika Pandhi, Ananta Khurana
The advent of biologics in dermatologic treatment armentarium has added refreshing dimensions, for it is a major breakthrough. Several agents are now available for use. It is therefore imperative to succinctly comprehend their pharmacokinetics for their apt use. A concerted endeavor has been made to delve on this subject. The major groups of biologics have been covered and include: Drugs acting against TNF-α, Alefacept, Ustekinumab, Rituximab, IVIG and Omalizumab. The relevant pharmacokinetic characteristics have been detailed...
September 2014: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/24852042/information-contributed-by-meta-analysis-in-exposure-response-modeling-application-to-phase-2-dose-selection-of-guselkumab-in-patients-with-moderate-to-severe-psoriasis
#5
RANDOMIZED CONTROLLED TRIAL
Chuanpu Hu, Yasmine Wasfi, Yanli Zhuang, Honghui Zhou
Ustekinumab, a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds with high affinity to human interleukin (IL)-12 and IL-23, has been approved to treat patients with psoriasis. Guselkumab is a related human IgG1 monoclonal antibody in clinical development which specifically blocks IL-23. The objective of this study was to study the exposure-response relationship of guselkumab to guide dose selection for a Phase 2 study in patients with moderate-to-severe psoriasis. Data were available from a Phase 1 study of 47 healthy subjects and 24 patients with psoriasis who received various doses of guselkumab...
June 2014: Journal of Pharmacokinetics and Pharmacodynamics
https://www.readbyqxmd.com/read/24467968/biologic-therapies-in-inflammatory-bowel-disease
#6
REVIEW
Lawrence B Cohen, Radu M Nanau, Faustine Delzor, Manuela G Neuman
Inflammatory bowel disease, including its 2 entities ulcerative colitis and Crohn's disease, is a chronic medical condition characterized by the destructive inflammation of the intestinal tract. Biologics represent a class of therapeutics with immune intervention potential. These agents block the proinflammatory cascade that triggers the activation and proliferation of T lymphocytes at the level of the intestine, therefore reestablishing the balance between the pro- and anti-inflammatory messages. All 7 biologics showing clinical benefits in inflammatory bowel disease are monoclonal antibodies...
June 2014: Translational Research: the Journal of Laboratory and Clinical Medicine
https://www.readbyqxmd.com/read/24101949/ustekinumab-in-the-treatment-of-psoriatic-arthritis-latest-findings-and-clinical-potential
#7
Alice Gottlieb, Kirti Narang
Ustekinumab (UST) is a fully human immunoglobulin G1κ (IgG1κ) monoclonal antibody against common sub-unit p40 of interleukin-12 (IL-12) and interleukin-23 (IL-23). IL-12 and IL-23 are essential components of the Th1 and Th17 inflammatory pathways, respectively, and are the key mediators of psoriasis. Psoriatic arthritis (PsA), an important systemic inflammatory disorder, has similar pathogenesis to psoriasis. Many of PsA patients do not respond to tumor necrosis factor (TNF) inhibitor therapy, highlighting the need for additional treatment modalities with distinct mechanisms of action...
October 2013: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/23902548/ustekinumab-for-the-treatment-of-crohn-s-disease
#8
REVIEW
Reena Khanna, Brian G Feagan
Crohn's disease (CD) results from a pathological immune response to luminal antigens in genetically predisposed individuals. Since the causes of CD are complex and only partially understood, treatment is based on the empiric use of anti-inflammatory drugs. Although multiple therapies for CD currently exist, a substantial proportion of patients are unresponsive to conventional agents. Approximately a third of patients fail treatment with TNF antagonists, and up to 40% of patients who initially benefit subsequently lose response...
August 2013: Immunotherapy
https://www.readbyqxmd.com/read/23512638/comparison-of-the-pharmacokinetics-of-subcutaneous-ustekinumab-between-chinese-and-non-chinese-healthy-male-subjects-across-two-phase-1-studies
#9
RANDOMIZED CONTROLLED TRIAL
Yaowei Zhu, Qingmin Wang, Bart Frederick, Esther Bouman-Thio, Joseph C Marini, Monica Keen, Kevin J Petty, Hugh M Davis, Honghui Zhou
BACKGROUND AND OBJECTIVE: Ustekinumab, a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody against interleukin-12/23p40, has been reported to be significantly efficacious in treating patients with moderate-to-severe plaque psoriasis. Although the efficacy and safety of ustekinumab have been previously studied in Asian patients with psoriasis, the pharmacokinetics of ustekinumab has not been reported for Asian patients. The objective of this analysis was to compare the pharmacokinetics of ustekinumab in Chinese and non-Chinese subjects...
April 2013: Clinical Drug Investigation
https://www.readbyqxmd.com/read/23295705/the-future-of-inflammatory-bowel-disease-therapy-where-do-we-go-from-here
#10
REVIEW
William J Sandborn
There are six important trends that will impact the future of inflammatory bowel disease therapy. (1) Increased use of the biomarkers C-reactive protein (CRP) and fecal calprotectin, and increased imaging with colonoscopy and MRI enterography. (2) Increased use of pharmacokinetics to customize drug dosing for individual patients. Multiple factors impact the pharmacokinetics of monoclonal antibodies including the presence of antidrug antibodies, concomitant immunosuppression and low serum albumin and high CRP concentrations...
2012: Digestive Diseases
https://www.readbyqxmd.com/read/22859234/the-safety-of-ustekinumab-in-psoriasis
#11
REVIEW
Shannon Famenini, Jashin J Wu
Ustekinumab is effective in the treatment of a variety of autoimmune conditions including psoriasis. As a relatively new therapeutic agent, its long-term effects are still under investigation. Short-term studies, however, have revealed ustekinumab to be generally well tolerated and safe. This article provides a comprehensive review of the pharmacokinetics of ustekinumab, its safety profile, adverse effects, and use in pregnancy. The effect of diabetes and prior immunosuppressant therapy is also addressed.
August 2012: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/22758912/is-class-effect-relevant-when-assessing-the-benefit-risk-profile-of-a-biologic-agent
#12
W Sterry, P van de Kerkhof
Psoriasis is a chronic, genetically predisposed skin disorder, characterised by thickened scaly plaques. Although no therapy is recognised as curative, therapies aimed at symptom control include biologic agents that are generally designed to block molecular activation of cellular pathways of a pathogenic immune response. Although biologics are often described as a class, they can be further sub-classified according to properties including structure and molecular target. For example, the two main groups of biologics for the treatment of psoriasis are those targeting cytokines and those targeting T-cells or antigen-presenting cells...
August 2012: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/21688068/bounded-outcome-score-modeling-application-to-treating-psoriasis-with-ustekinumab
#13
RANDOMIZED CONTROLLED TRIAL
Chuanpu Hu, Newman Yeilding, Hugh M Davis, Honghui Zhou
Disease status is often measured with bounded outcome scores (BOS) which report a discrete set of values on a finite range. The distribution of BOS data is often non-standard, e.g., J- or U-shaped, thus making standard analysis methods that assume normality inappropriate. Data transformations aiming to achieve normality with BOS can be much more difficult than with many other types of skewed distributions, and application of methodologies explicitly dealing with this problem has not been previously published in pharmacokinetic/pharmacodynamic modeling literature...
August 2011: Journal of Pharmacokinetics and Pharmacodynamics
https://www.readbyqxmd.com/read/21084039/population-pharmacokinetics-of-ustekinumab-in-patients-with-active-psoriatic-arthritis
#14
RANDOMIZED CONTROLLED TRIAL
Y W Zhu, A Mendelsohn, C Pendley, H M Davis, H Zhou
PURPOSE: To characterize the population pharmacokinetics of subcutaneous ustekinumab, a human IgG1Kappa; monoclonal antibody against interleukin-12/23p40, using data from a randomized, double-blind, placebo-controlled Phase II study in patients with active psoriatic arthritis (PsA). METHODS: A total of 786 quantifiable serum ustekinumab concentrations from 130 patients were analyzed using a nonlinear mixed-effects modeling approach. A 1-compartment model with first-order absorption and elimination was selected as the structural model...
December 2010: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/20599293/impact-of-weight-on-the-efficacy-and-safety-of-ustekinumab-in-patients-with-moderate-to-severe-psoriasis-rationale-for-dosing-recommendations
#15
RANDOMIZED CONTROLLED TRIAL
Mark Lebwohl, Newman Yeilding, Philippe Szapary, Yuhua Wang, Shu Li, Yaowei Zhu, Kristian Reich, Richard G Langley, Kim A Papp
BACKGROUND: Patients with psoriasis tend to be overweight, and the efficacy of fixed-dose biologics may be compromised by high body weight. OBJECTIVE: We sought to determine whether the optimal dose of ustekinumab is affected by weight in patients with psoriasis. METHODS: Patients were randomized in two phase III trials (PHOENIX 1 and 2) to receive 45 mg or 90 mg of ustekinumab every 12 weeks (n = 1331) or placebo with crossover to ustekinumab at week 12 (n = 665)...
October 2010: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/20218921/the-use-of-ustekinumab-in-autoimmune-disease
#16
REVIEW
Caitriona Ryan, Breck Thrash, Richard B Warren, Alan Menter
IMPORTANCE OF THE FIELD: The advent of biologic therapies has revolutionized the treatment of autoimmune diseases including psoriasis, autoimmune arthritides and inflammatory bowel disease. With recent advances in our understanding of the immunogenetic pathways involved in the pathogenesis of these conditions, newer, more targeted biologic therapies have been developed. Ustekinumab is an antibody to the common p40 subunit of IL-12 and IL-23, which has been studied in the treatment of psoriasis, psoriatic arthritis, Crohn's disease and multiple sclerosis...
April 2010: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/19671802/ustekinumab-treatment-of-adult-moderate-to-severe-chronic-plaque-psoriasis
#17
REVIEW
James V Scanlon, Benjamin P Exter, Michael Steinberg, Courtney I Jarvis
OBJECTIVE: To systematically review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of ustekinumab to inform pharmacists and other healthcare professionals of this new biologic therapy for psoriasis. DATA SOURCES: A search of PubMed/MEDLINE, EMBASE, and International Pharmaceutical Abstracts was performed through July 2009, limited to publications in English, using the search terms CNTO-1275, ustekinumab, interleukin-12, interleukin-23, and/or psoriasis to identify literature sources...
September 2009: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/19179295/population-pharmacokinetic-modeling-of-ustekinumab-a-human-monoclonal-antibody-targeting-il-12-23p40-in-patients-with-moderate-to-severe-plaque-psoriasis
#18
Yaowei Zhu, Chuanpu Hu, Ming Lu, Sam Liao, Joseph C Marini, Jennifer Yohrling, Newman Yeilding, Hugh M Davis, Honghui Zhou
The population pharmacokinetics of ustekinumab are characterized in patients with moderate to severe plaque psoriasis in 2 Phase 3 studies (PHOENIX 1 and PHOENIX 2). Serum concentration data from 1937 patients are analyzed to determine pharmacokinetic characteristics of ustekinumab and to assess factors that may contribute to their variability. The population typical mean (percentage relative standard error) values for apparent clearance, apparent volume of distribution, and absorption rate constant from the final covariate model are 0...
February 2009: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/18703004/repeated-subcutaneous-injections-of-il12-23-p40-neutralising-antibody-ustekinumab-in-patients-with-relapsing-remitting-multiple-sclerosis-a-phase-ii-double-blind-placebo-controlled-randomised-dose-ranging-study
#19
RANDOMIZED CONTROLLED TRIAL
Benjamin M Segal, Cris S Constantinescu, Aparna Raychaudhuri, Lilianne Kim, Rosanne Fidelus-Gort, Lloyd H Kasper
BACKGROUND: Repeated subcutaneous injections of a monoclonal antibody against the p40 subunit of interleukins 12 and 23, ustekinumab, were used to treat patients with relapsing-remitting multiple sclerosis (RRMS) to assess the drug's safety, efficacy, and pharmacokinetics. METHODS: In this phase II, multicentre, randomised, double-blind, placebo-controlled study, 249 patients with RRMS, aged 18-65 years, were eligible to be assigned equally (by a central randomisation procedure based on study site and presence or absence of gadolinium-enhancing T1-weighted lesions at baseline) to one of five groups that received placebo or four different ustekinumab dosages at weeks 0, 1, 2, 3, 7, 11, 15, and 19...
September 2008: Lancet Neurology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"